⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 1, 2025

Supplementary Figure 2 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine

Ernesto Bermúdez-Abreut Gretchen Bergado Talia Fundora-Barrios Jessica Arencibia-Perezleo Armando López Medinilla Lisset Chao Belinda Sánchez-Ramírez

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Inclusion of HER1 or HER2 with a HER3 vaccine enhances antitumor effects.
KEY EVIDENCE: Immunizations produced varied anti-HER3 antibody titers across three different vaccine designs.
APPROACH: The study compares antibody responses following four immunizations with HER3-based vaccine candidates.
SIGNIFICANCE: Findings could inform future cancer vaccine strategies by maximizing antibody production.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Comparison of anti-HER3 antibody titers from three vaccine candidates, suggesting enhanced efficacy with HER1 or HER2 inclusion.

Abstract

Comparison of anti-HER3 antibody titers generated after four immunizations with the three HER3-based vaccine candidates.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bermúdez-Abreut et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfc96 https://doi.org/10.1158/1535-7163.29761171

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
2Supplementary Figure 4 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
3Supplementary Figure 1 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
4Data from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
5Supplementary Figure S7 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024
6Supplementary Figure S7 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024
7Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024
8Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024